In conclusion, we currently observe the kinetic changes of IL‐6, PCT, and CRP to investigate their role in initial antibiotic efficacy evaluation of FN patients with hematological disorder, confirming IL‐6 and CRP as the biomarkers. This evidence concerns the gene IL6 and hematologic disorder.